Arteriovenous fistula (AVF) access is one of the key areas that is set to receive a boost following MedAlliance’s acquisition of its partner MDK Medical—according to a company press release.
MDK Medical has previously worked closely with MedAlliance in developing Japanese clinical studies for its novel sirolimus drug-eluting balloon (DEB), Selution SLR, in the treatment of peripheral arterial disease (PAD).
This recent acquisition will, however, facilitate expansion of the Japanese clinical trial programme beyond PAD to areas including diseases of the inferior femoral artery, AVF access for dialysis in kidney disease patients, and a DEB intended to treat erectile dysfunction.
“We are very excited to have acquired MDK Medical, as we now have direct access to the Japanese market”, said MedAlliance chairman and CEO Jeffrey B Jump. “We will be focusing on gaining approval for Selution SLR in Japan—one of the world’s most important markets”.
Selution SLR was awarded CE mark approval for the treatment of PAD in February 2020 and for the treatment of coronary arterial disease in May 2020, while the US Food and Drug Administration (FDA) has granted Selution SLR four breakthrough designations.
These concern the treatment of atherosclerotic lesions in native coronary arteries; coronary in-stent restenosis; peripheral below-the-knee; and AVF indications.
